Keyword: Dana-Farber Cancer Institute
Eli Lilly doubles down on its collaboration with the Dana-Farber Cancer Institute, extending the partnership for another three years.
Chief Scientific Officer Andrew Phillips was named CEO of C4 Therapeutics, a 2016 Fierce 15 winner.
The thoracic oncologist will head up a team tasked with overseeing the advance of Lilly’s portfolio of immuno-oncology prospects.
Researchers are combining immunotherapies and attacking tumor defenses in efforts to improve checkpoint inhibitors.
Scientists at Dana-Farber Cancer Institute and Harvard have invented an immunotherapy “gel” that’s placed at the surgery site and is showing promising results in mouse models.
Novartis foresees next-generation immunotherapies that use biodegradable implants and injectable systems to trigger long-lasting attacks on tumors.
At the annual ASH meeting, oncologists at the Dana-Farber Cancer Institute demonstrated how simple blood tests may hold promise for managing multiple myeloma.
Daiichi Sankyo has added a preclinical lung cancer collaboration with Dana-Farber Cancer Institute to its fast-growing list of oncology alliances.
Dr. Richard Gaynor will leave his position as one of the top execs of Eli Lilly’s Oncology division at the start of next year as the company employs new blood to try to bolster its cancer R&D.